|Bid||96.70 x 1300|
|Ask||97.06 x 800|
|Day's Range||96.47 - 97.96|
|52 Week Range||60.63 - 100.43|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||11.22|
|Earnings Date||Oct 22, 2018 - Oct 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.93|
SAN DIEGO and ST. LOUIS, Nov. 19, 2018 /PRNewswire/ -- Petco and Express Scripts (ESRX), a healthcare company focused on delivering personalized solutions to improve healthcare, today announced a new strategic alliance that will enable millions of pet parents to order and receive pet medicines from the comfort and convenience of home. Pet parents spend more than $8 billion annually on prescription and over-the-counter (OTC) medications for their animals. Petco now offers pet parents access to the pet prescriptions and OTC medications their pets need online via petco.com and petcoach.co for delivery directly to their front door, all Powered by Express Scripts.
The list prices that pharmaceutical companies set for their drugs diverge wildly from their real cost, and PBMs widen and feast on the gap, which helps make them some of the principal beneficiaries of America’s byzantine pricing system. One of the main services PBMs provide are so-called drug formularies, or tiered lists of medicines, where drugs deemed “preferred” are much cheaper than those that are “excluded.” Preferred status on a major formulary can add millions in sales volume, and drugmakers offer huge rebates in order to secure it.
Walmart (WMT.N) and Home Depot (HD.N), two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.
- New National Preferred Flex Formulary provides employers and health plans a pathway to cover lower list price products, help deliver lower member out-of-pocket costs, and reduce reliance on brand rebates. - Authorized alternatives for hepatitis C therapies Epclusa® and Harvoni® among first products to be available through Express Scripts' National Preferred Flex Formulary. ST. LOUIS, Nov. 13, 2018 /PRNewswire/ -- As drug pricing strategies continue to evolve, Express Scripts (ESRX) is keeping clients ahead of the game.
Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.
ST. LOUIS and TAMPA, Fla. , Nov. 6, 2018 /PRNewswire/ -- myMatrixx®, a leader in pharmacy services for workers' compensation programs and a subsidiary of Express Scripts Holding Company (NASDAQ: ESRX), ...
Almost 170,000 square feet of positive absorption took place during the third quarter, with the Cortex tech district leading the way with 90,000 square feet.
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Cigna merger is on track, and we are maintaining our $92 fair value estimate and wide moat rating after a solid quarter for Express Scripts.
Cigna Corp said on Thursday its $52-billion acquisition of pharmacy benefits manager Express Scripts Holding Co was on track to close by the end of the year. Chief Executive Officer David Cordani said ...
Express Scripts' (ESRX) Q3 results hurt by year-over-year decline in adjusted network claims, thanks to the loss of certain public sector clients.
Investing.com - Express Scripts (NASDAQ:ESRX) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
Express Scripts (ESRX) delivered earnings and revenue surprises of 0.41% and 2.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ExpressScripts stock (NASDAQ:ESRX) did not experience much movement late in the day Wednesday as the company unveiled its latest quarterly earnings results, which were just a touch above what analysts were calling for in their consensus estimate. When adjusted for one-time gains and costs, ExpressScripts brought in earnings of $2.43 per share. The figure was slightly ahead of what the Wall Street consensus estimate projected as the average guidance of 11 analysts surveyed by Zacks Investment Research called for net income of $2.42 per share.
The St. Louis-based company said it had profit of $1.89 per share. Earnings, adjusted for one-time gains and costs, came to $2.43 per share. The results beat Wall Street expectations. The average estimate ...
Express Scripts CEO Tim Wentworth explains at our Capital Exchange: Longevity Economy event in DC that with close to 25% of his employees over 50, there’s varying degrees of skill adaptation. He’s seen an inclusive culture that that allows people to he...
Cigna President and CEO David Cordani joins 'Squawk on the Street' to discuss the company's quarterly earnings, the pending merger with Express Scripts, future growth and medical marijuana.